Invasive streptococcal disease: A review for clinicians

British Medical Bulletin

Volumn 115, Issue 1, 2015, Pages 77-89

  Parks, Tom ^a   Barrett, Lucinda ^b   Jones, Nicola ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

anti bacterials; bacteraemia; endocarditis; intravenous immunoglobulins; meningitis; puerperal infection; sepsis; septic shock; soft tissue infections; streptococcus

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BACTERIAL VACCINE; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CLINDAMYCIN; IMMUNOGLOBULIN; MACROLIDE; PENICILLIN G; TETRACYCLINE; VANCOMYCIN; STREPTOCOCCUS VACCINE;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CHEMOPROPHYLAXIS; CLASSIFICATION; CLINICAL FEATURE; DISABILITY; GROUP A STREPTOCOCCAL INFECTION; GROUP B STREPTOCOCCAL INFECTION; HEALTH CARE COST; HUMAN; INFECTION PREVENTION; MORTALITY; NOMENCLATURE; PNEUMOCOCCAL INFECTION; PREGNANT WOMAN; PRIORITY JOURNAL; SCREENING; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS ANGINOSUS; STREPTOCOCCUS EQUINUS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS GROUP C; STREPTOCOCCUS GROUP G; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; STREPTOCOCCUS ZOONOSIS; ZOONOSIS; EVIDENCE BASED MEDICINE; PROCEDURES; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; UNITED KINGDOM;

EVIDENCE-BASED MEDICINE; HUMANS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PYOGENES; UNITED KINGDOM;

EID: 84941205210     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldv027     Document Type: Article

References (101)

1. O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009;374:893-902.
2. Lancefield RC. A serological differentiation of human and other groups of hemolytic streptococci. J Exp Med 1933;57:571-95.
3. Facklam R. What happened to the streptococci: overview of taxonomic and nomenclature changes. Clin Microbiol Rev 2002;15:613-30.
4. Doern CD, Burnham CAD. It's not easy being green: the viridans group streptococci, with a focus on pediatric clinical manifestations. J Clin Microbiol 2010;48:3829-35.
5. Steer AC, Lamagni TL, Curtis N, et al. Invasive group A streptococcal disease-epidemiology, pathogenesis and management. Drugs 2012;72:1213-27.
6. Efstratiou A. Group A streptococci in the 1990s. J Antimicrob Chemother 2000;45(Suppl):3-12.
7. Lamagni TL, Neal S, Keshishian C, et al. Severe Streptococcus pyogenes infections, United Kingdom, 2003-2004. Emerging Infect Dis 2008;14:202-9.
8. Lamagni TL, Neal S, Keshishian C, et al. Predictors of death after severe Streptococcus pyogenes infection. Emerging Infect Dis 2009;15:1304-7.
9. Hughes GJ, van Hoek AJ, Sriskandan S, et al. The cost of hospital care for management of invasive group A streptococcal infections in England. Epidemiol Infect 2015;143:1719-30.
10. Lamagni TL, Efstratiou A, Dennis J, et al. Increase in invasive group A streptococcal infections in England, Wales and Northern Ireland, 2008-9. Euro Surveill 2009;14:1-2.
11. Guy R, Williams C, Irvine N, et al. Increase in scarlet fever notifications in the United Kingdom, 2013/2014. Euro Surveill 2014;19:20749.
12. Giuliano A, Lewis F, Hadley K, et al. Bacteriology of necrotizing fasciitis. Am J Surg 1977;134:52-7.
13. Sriskandan S. Severe peripartum sepsis. J R Coll Physicians Edinb 2011;41:339-46.
14. Kramer HMC, Schutte JM, Zwart JJ, et al. Maternal mortality and severe morbidity from sepsis in the Netherlands. Acta Obstet Gynecol Scand 2009;88:647-53.
15. Acosta CD, Kurinczuk JJ, Lucas DN, et al. Severe maternal sepsis in the UK, 2011-2012: a national case-control study. PLoS Med 2014;11:e1001672.
16. Cantwell R, Clutton-Brock T, Cooper G, et al. Saving Mothers' Lives: reviewing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011;118(Suppl. 1):1-203.
17. Stevens DL. Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment. Emerging Infect Dis 1995;1:69-78.
18. Lamagni TL, Darenberg J, Luca-Harari B, et al. Epidemiology of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol 2008;46:2359-67.
19. Lamagni TL, Neal S, Keshishian C, et al. Severe Streptococcus pyogenes infections, United Kingdom, 2003-2004. Emerging Infect Dis 2008;14:202-9.
20. Proft T, Sriskandan S, Yang L, et al. Superantigens and streptococcal toxic shock syndrome. Emerging Infect Dis 2003;9:1211-8.
21. Walker MJ, Barnett TC, McArthur JD, et al. Disease manifestations and pathogenic mechanisms of group a streptococcus. Clin Microbiol Rev 2014;27:264-301.
22. Reglinski M, Sriskandan S. The contribution of group A streptococcal virulence determinants to the pathogenesis of sepsis. Virulence 2014;5:127-36.
23. Eron LJ, Lipsky BA, Low DE, et al. Managing Skin and Soft Tissue Infections: Expert Panel Recommendations on Key Decision Points. Oxford, UK: Oxford University Press, 2003.
24. Chuang I, Van Beneden C, Beall B, et al. Population-based surveillance for postpartum invasive group a streptococcus infections, 1995-2000. Clin Infect Dis 2002;35:665-70.
25. Lamagni TL, Neal S, Keshishian C, et al. Epidemic of severe Streptococcus pyogenes infections in injecting drug users in the UK, 2003-2004. Clin Microbiol Infect 2008;14:1002-9.
26. Lamb LEM, Sriskandan S, Tan LKK. Bromine, bear-claw scratch fasciotomies, and the Eagle effect: management of group A streptococcal necrotising fasciitis and its association with trauma. Lancet Infect Dis 2015;15:109-21.
27. Horn DL, Zabriskie JB, Austrian R, et al. Why have group A streptococci remained susceptible to penicillin? Report on a symposium. Clin Infect Dis 1998;26:1341-5.
28. Sriskandan S, McKee A, Hall L, et al. Comparative effects of clindamycin and ampicillin on superantigenic activity of Streptococcus pyogenes. J Antimicrob Chemother 1997;40: 275-7.
29. Linnér A, Darenberg J, Sjölin J, et al. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 2014;59:851-7.
30. Carapetis JR, Jacoby P, Carville K, et al. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. Clin Infect Dis 2014;59:358-65.
31. Agency HP. Pyogenic and non-pyogenic streptococcal bacteraemia, England, Wales and Northern Ireland: 2010. Health Protection Report 2011;5.
32. Norrby-Teglund A, Kaul R, Low DE, et al. Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect Immun 1996;64:5395-8.
33. Tan LKK, Sriskandan S. Editorial commentary: step on the GAS: are we almost there for clindamycin and intravenous immunoglobulin? Clin Infect Dis 2014;59:366-8.
34. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome- A comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 1999;28:800-7.
35. Darenberg J, Ihendyane N, Sjölin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003;37:333-40.
36. Department of Health. Clinical Guidelines for Immunoglobulin Use. London: Department of Health, 2008.
37. Steer JA, Lamagni T, Healy B, et al. Guidelines for prevention and control of group A streptococcal infection in acute healthcare and maternity settings in the UK. J Infect 2012;64:1-18.
38. Smith A, Lamagni TL, Oliver I, et al. Invasive group A streptococcal disease: should close contacts routinely receive antibiotic prophylaxis? Lancet Infect Dis 2005; 5:494-500.
39. Davies HD, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med 1996;335:547-54.
40. Robinson KA, Rothrock G, Phan Q, et al. Risk for severe group A streptococcal disease among patients' household contacts. Emerging Infect Dis 2003;9:443-7.
41. Purcell B, Samuelsson S, Hahn S, et al. Effectiveness of antibiotics in preventing meningococcal disease after a case: systematic review. BMJ 2004;328:1339-1342A.
42. Health Protection Agency Group A Streptococcus Working Group. Interim UK guidelines for management of close community contacts of invasive group A streptococ-cal disease. Commun Dis Public Health 2004;7:354-61.
43. Steer AC, Dale JB, Carapetis JR. Progress toward a global group a streptococcal vaccine. Pediatr Infect Dis J 2013;32:180-2.
44. Edmond KM, Kortsalioudaki C, Scott S, et al. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 2012;379:547-56.
45. Verani JR, McGee L, Schrag SJ, et al. Prevention of Perinatal Group B Streptococcal Disease-Revised Guidelines From CDC, 2010. MMWR Recomm Rep 2010;59(RR-10):1-36.
46. Lamagni TL, Keshishian C, Efstratiou A, et al. Emerging trends in the epidemiology of invasive group B strepto-coccal disease in England and Wales, 1991-2010. Clin Infect Dis 2013;57:682-8.
47. Baker CJ, Barrett FF. Transmission of group B streptococci among parturient women and their neonates. J Pediatr 1973; 83: 919-25.
48. Hussain SM, Luedtke GS, Baker CJ, et al. Invasive group B streptococcal disease in children beyond early infancy. Pediatr Infect Dis J 1995;14:278-81.
49. Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008;299:2056-65.
50. Berardi A, Rossi C, Lugli L, et al. Group B streptococcus late-onset disease: 2003-2010. Pediatrics 2013;131:e361-8.
51. National Institute for Health and Clinical Excellence. Antibiotics for Early-Onset Neonatal Infection-Guidance and Guidelines-NICE. London: National Clinical Guideline Centre, 2012.
52. Weston EJ, Pondo T, Lewis MM, et al. The burden of invasive early-onset neonatal sepsis in the United States, 2005-2008. Pediatr Infect Dis J 2011;30:937-41.
53. Compain F, Hays C, Touak G, et al. Molecular characterization of Streptococcus agalactiae isolates harboring small erm(T)-carrying plasmids. Antimicrob Agents Chemother 2014;58:6928-30.
54. Royal College of Obstetricians and Gynaecologists. Prevention of Early Onset Neonatal GBS Infection. London: Royal College of Obstetricians and Gynaecologists, 2012.
55. Ohlsson A, Shah VS. Intrapartum antibiotics for known maternal Group B streptococcal colonization. Cochrane Database Syst Rev 2014;6:CD007467.
56. Daniels JP, Gray J, Pattison HM, et al. Intrapartum tests for group B streptococcus: accuracy and acceptability of screening. BJOG 2011;118:257-65.
57. Melin P, Efstratiou A. Group B streptococcal epidemiology and vaccine needs in developed countries. Vaccine 2013;31(Suppl. 4):D31-42.
58. Knowles S, O'Sullivan N, Meenan A, et al. Maternal sepsis incidence, aetiology and outcome for mother and fetus: a prospective study. BJOG 2014;121:1754-5.
59. Skoff TH, Farley MM, Petit S, et al. Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007. Clin Infect Dis 2009;49:85-92.
60. Edwards MS, Baker CJ. Group B streptococcal infections in elderly adults. Clin Infect Dis 2005;41:839-47.
61. Farley MM. Group B streptococcal infection in older patients. Spectrum of disease and management strategies. Drugs Aging 1995;6:293-300.
62. Jensen A, Kilian M. Delineation of Streptococcus dysga-lactiae, its subspecies, and its clinical and phylogenetic relationship to Streptococcus pyogenes. J Clin Microbiol 2012;50:113-26.
63. Brandt CM, Spellerberg B. Human infections due to Streptococcus dysgalactiae subspecies equisimilis. Clin Infect Dis 2009;49:766-72.
64. ESPAUR Writing Committee. English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR), Technical report. London, 2014.
65. Public Health England. Chapter 25: Pneumococcal: the green book. In: Salisbury D, Ramsay M (eds). Immunisation Against Infectious Disease. London, 2013.
66. Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med 2014;371:1619-28.
67. Wei BPC, Shepherd RK, Robins-Browne RM, et al. Pneumococcal meningitis post-cochlear implantation: potential routes of infection and pathophysiology. Otolaryngol Head Neck Surg 2010;143:S15-23.
68. Lim WS, Baudouin SV, George RC, et al. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults: Update 2009. Thorax 2009;64(Suppl 3): iii1-55.
69. Sinclair A, Xie X, Teltscher M, et al. Systematic review and meta-analysis of a urine-based pneumococcal antigen test for diagnosis of community-acquired pneumonia caused by Streptococcus pneumoniae. J Clin Microbiol 2013;51:2303-10.
70. van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004;351:1849-59.
71. van de Beek D, Farrar JJ, de Gans J, et al. Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data. Lancet Neurol 2010;9:254-63.
72. Chapter 200: Streptococcus pneumoniae. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Churchill Livingstone, 2010, 2623-42.
73. El Moussaoui R, de Borgie CAJM, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 2006;332:1355.
74. National Institute for Health and Clinical Excellence. Pneumonia: Diagnosis and Management of Community-and Hospital-Acquired Pneumonia in Adults [CG191]. London: National Clinical Guideline Centre, 2014.
75. Marrie TJ, Tyrrell GJ, Garg S, et al. Factors predicting mortality in invasive pneumococcal disease in adults in Alberta. Medicine (Baltimore) 2011;90:171-9.
76. Mehr S, Wood N. Streptococcus pneumoniae- A review of carriage, infection, serotype replacement and vaccination. Paediatr Respir Rev 2012;13:258-64.
77. Selton-Suty C, Celard M, Le Moing V, et al. Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis 2012;54:1230-9.
78. Hoen B, Alla F, Selton-Suty C, et al. Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA 2002;288:75-81.
79. Gould FK, Denning DW, Elliott TSJ, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012;67:269-89.
80. Tunkel AR, Sepkowitz KA. Infections caused by viri-dans streptococci in patients with neutropenia. Clin Infect Dis 2002;34:1524-9.
81. Dayer MJ, Jones S, Prendergast B, et al. Incidence of infective endocarditis in England, 2000-13: a secular trend, interrupted time-series analysis. Lancet 2015; 385:1219-28.
82. Whiley RA, Beighton D, Winstanley TG, et al. Streptococcus intermedius, Streptococcus constellatus, and Streptococcus anginosus (the Streptococcus milleri group): association with different body sites and clinical infections. J Clin Microbiol 1992;30:243-4.
83. Nagashima H, Takao A, Maeda N. Abscess forming ability of streptococcus milleri group: synergistic effect with Fusobacterium nucleatum. Microbiol Immunol 1999;43:207-16.
84. Kowlessar PI, O'Connell NH, Mitchell RD, et al. Management of patients with Streptococcus milleri brain abscesses. J Infect 2006;52:443-50.
85. Bert F, Bariou-Lancelin M, Lambert-Zechovsky N. Clinical significance of bacteremia involving the 'Streptococcus milleri' group: 51 cases and review. Clin Infect Dis 1998;27:385-7.
86. Molina JM, Leport C, Bure A, et al. Clinical and bacterial features of infections caused by Streptococcus milleri. Scand J Infect Dis 1991;23:659-66.
87. Lefort A, Lortholary O, Casassus P, et al. Comparison between adult endocarditis due to beta-hemolytic streptococci (serogroups A, B, C, and G) and Streptococcus milleri: a multicenter study in France. Arch Intern Med 2002;162:2450-6.
88. Jans C, Meile L, Lacroix C, et al. Genomics, evolution, and molecular epidemiology of the Streptococcus bovis/Streptococcus equinus complex (SBSEC). Infect Genet Evol 2014.
89. Abdulamir AS, Hafidh RR, Mahdi LK, et al. Investigation into the controversial association of Streptococcus gallolyticus with colorectal cancer and adenoma. BMC Cancer 2009;9:403.
90. Potter MA, Cunliffe NA, Smith M, et al. A prospective controlled study of the association of Streptococcus bovis with colorectal carcinoma. J Clin Pathol 1998;51: 473-4.
91. Chirouze C, Patry I, Duval X, et al. Streptococcus bovis/Streptococcus equinus complex fecal carriage, colorectal carcinoma, and infective endocarditis: a new appraisal of a complex connection. Eur J Clin Microbiol Infect Dis 2013;32:1171-6.
92. Murdoch DR, Corey GR, Hoen B, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 2009;169:463-73.
93. Corredoira J, Alonso MP, Coira A, et al. Characteristics of Streptococcus bovis endocarditis and its differences with Streptococcus viridans endocarditis. Eur J Clin Microbiol Infect Dis 2008;27:285-91.
94. Boleij A, Muytjens CMJ, Bukhari SI, et al. Novel clues on the specific association of Streptococcus gallolyticus subsp gallolyticus with colorectal cancer. J Infect Dis 2011;203:1101-9.
95. Zarkin BA, Lillemoe KD, Cameron JL, et al. The triad of Streptococcus bovis bacteremia, colonic pathology, and liver disease. Ann Surg 1990;211:786-91. discussion 791-2.
96. Linder JD, Mönkemüller KE, Lazenby AJ, et al. Streptococcus bovis bacteremia associated with Strongyloides stercoralis colitis. Gastrointest Endosc 2000;52:796-8.
97. Cohen LF, Dunbar SA, Sirbasku DM, et al. Streptococcus bovis infection of the central nervous system: report of two cases and review. Clin Infect Dis 1997;25:819-23.
98. Wertheim HFL, Nghia HDT, Taylor W, et al. Streptococcus suis: an emerging human pathogen. Clin Infect Dis 2009;48:617-25.
99. Mai NTH, Hoa NT, Nga TVT, et al. Streptococcus suis meningitis in adults in Vietnam. Clin Infect Dis 2008; 46:659-67.
100. Yu H, Jing H, Chen Z, et al. Human Streptococcus suis outbreak, Sichuan, China. Emerging Infect Dis 2006; 12:914-20.
101. Jasir A, Schalén C, Strep-ERUO study group. Strep-EURO: progress in analysis and research into severe streptococcal disease in Europe, 2003-2004. Euro Surveill 2005;10:E050203.3.